Discover why Hims & Hers Health (HIMS) remains a strong long-term buy after robust Q3 growth, new offerings, and expansion ...

Hims & Hers Health (NYSE:HIMS) said it is holding discussions with Novo Nordisk (NYSE:NVO) to make the Danish drugmaker's ...

Hims & Hers Health (HIMS) stock rises as the company renews talks with Novo Nordisk (NVO) to sell the pharma giant's obesity drug Wegovy. Read more here.

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Hims and Hers Health Inc. rose after the telehealth company said it was in talks with Novo Nordisk A/S to sell its ...

Hims & Hers Health narrowed its full-year guidance following mixed third-quarter results as the telehealth platform continued to post strong subscriber and revenue growth.

Market observers now await further developments regarding the potential Novo Nordisk partnership. Should Hims & Hers successfully secure the Wegovy distribution agreement, the company could maintain ...

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.